 Similar outcome treatment B-cell T-cell large-cell lymphomas Stanford experience previous studies poor prognosis patients peripheral T-cell lymphoma clinical significance immunologic phenotype diffuse large-cell lymphoma DLCL controversial patients uniform morphologic diagnosis DLCL Stanford cyclophosphamide Adriamycin doxorubicin Adria Columbus OH vincristine prednisone CHOP methotrexate bleomycin Adriamycin cyclophosphamide vincristine dexamethasone BACOD methotrexate Adriamycin cyclophosphamide vincristine prednisone bleomycin MACOP-B chemotherapy regard phenotype Immunologic analysis frozen paraffin-embedded tissue cases B-cell origin cases T-cell origin cases B-cell T-cell markers Analysis complete remission CR rates actuarial freedom disease progression actuarial overall survival significant differences prognosis B- T-cell patients actuarial survival patients stage IV T-cell DLCL significant way stage IV B-cell patients treatment selection DLCL immunologic phenotype